Loading...
NPI 1780630608 · Charlottesville, VA · General Acute Care Hospital
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Rector & Visitors Of The University Of Virginia is a general acute care hospital provider located in Charlottesville, Virginia. This profile covers 0 Medicare and 1033 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Rector & Visitors Of The University Of Virginia |
| Address | 1215 Lee St Pfs |
| City | Charlottesville |
| State | VA |
| ZIP | 22908 |
| Taxonomy | General Acute Care Hospital |
| NPI Enumerated | May 25, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $500.4M |
| Medicare | $0 |
RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA is effectively a Medicaid-focused billing entity with no Medicare revenue on file; its reported lifetime Medicaid revenue is $500.4M and the provider has no Medicare billing recorded, making its public payer footprint single-payer in the available data. This concentration means analyses of its utilization and market role should be interpreted through the Medicaid lens rather than a combined Medicare/Medicaid mix.
Revenue concentration is high: the top 3 Medicaid codes by revenue account for 51.1% of the provider’s total Medicaid revenue, indicating that a small set of services dominates financial performance. The leading single code is 99214, which alone contributes $71.3M (22.1% of Medicaid revenue), highlighting that outpatient evaluation and management visits are a primary revenue driver.
The code mix indicates a large ambulatory volume and a significant dialysis and infusion service line. High volumes and revenues for 99214, 99213, and 99212 (combined as major E/M clinic visit codes) show the provider operates extensive outpatient visit capacity, while 90935 and 90945 (hemodialysis-related codes) together represent a substantial dialysis business line with 90935 ranking #1 in-state.
This provider shows dominant in-state standing on many high-volume codes: 99214 and 99213 both rank #4 in-state and are described as “extreme outlier” volumes, while 90935 ranks #1 of 79 providers (100th percentile). Several other codes such as 90945, J1459, 96415, and J2350 also rank #1 in-state or in the top percentiles, signaling clinical service dominance in multiple specialties including dialysis, infusion/biologic therapies, and chemotherapy administration.
The payer/service implications of high-cost drug and infusion codes are notable: J9271 (pembrolizumab) and J1459 (IV immune globulin) together represent meaningful therapy revenue lines ($12.2M and $9.6M respectively), indicating the provider delivers specialty oncology and immunology outpatient infusions. These biologic and chemotherapy-related codes (including 96413/96415 and J2350) suggest integrated outpatient oncologic infusion and specialty drug services complementary to its ambulatory E/M volumes.
Operational intensity in emergency and observation services is also evident. Emergency E/M codes 99285, 99284, and 99283 together generate double-digit millions in revenue and G0378 (hospital observation service) produced $5M and ranks #2 in-state, indicating significant ED and observation throughput that complements the high ambulatory and infusion volumes.
The provider’s NPI was enumerated ~20 years ago (2006-05-25), indicating long tenure in the market; this longevity combined with the concentration of high-volume codes suggests established clinical programs and referral networks supporting sustained Medicaid activity.
Several codes are flagged as “extreme outlier” or “notably above typical” in state comparisons—examples include 99214, 99213, 99212, 96415, and 43239—pointing to utilization that is far above typical state volumes for those services. These statistical outlier labels reinforce that the provider is a major in-state hub for primary outpatient care, endoscopy, chemotherapy/infusion, and dialysis services.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1033 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 351,080 | $200 | $71.3M |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 246,910 | $210 | $50.6M |
| 90935 | Hemodialysis is a procedure that involves drawing blood via an intra–arterial or intravenous catheter, then sieving it through a semi permeable membrane to remove the impurities and finally… | 139,150 | $310 | $43M |
| 99212 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a straightforward level of medical decision making,… | 113,580 | $210 | $23.7M |
| J9271 | Injection, pembrolizumab, 1 mg | 2,060 | $5,920 | $12.2M |
| 90945 | The provider evaluates the patient and chooses one of several methods to perform dialysis, except hemodialysis. | 30,500 | $370 | $11.3M |
| 99285 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a high level of medical decision making. | 40,210 | $250 | $10M |
| 99284 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making. | 41,530 | $240 | $9.9M |
| J1459 | Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 7,130 | $1,350 | $9.6M |
| 99283 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a low level of medical decision making. | 38,250 | $250 | $9.4M |
Showing 1–10 of 1033
How this provider's Medicaid billing volume and revenue compare to other Virginia providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Virginia median
1033 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 2 | 10 | 800 | $5,190 | $4.6M |
| 96361 | The provider administers intravenous, or IV, fluids with electrolytes through an already established intravenous route for each additional hour to treat more severe dehydration. | 20 | 90 | 9,030 | $280 | $3.2M |
| J1459 | Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 1 | 10 | 700 | $1,300 | $2.8M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2 | 70 | 3,200 | $110 | $2.8M |
| 90945 | The provider evaluates the patient and chooses one of several methods to perform dialysis, except hemodialysis. | 1 | 10 | 5,860 | $230 | $2.3M |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 3 | 10 | 800 | $1,530 | $2.1M |
| J2350 | Injection, ocrelizumab, 1 mg | 1 | 10 | 20 | $18,310 | $1.9M |
| 41899 | Use this code to report a procedure on the teeth and adjoining alveolar structures for which there is no specific code available. | 19 | 30 | 600 | $1,370 | $1.7M |
| S9342 | Home therapy; enteral nutrition via pump; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (enteral formula and nursing visits… | 15 | 20 | 1,070 | $370 | $1.6M |
| J0178 | Injection, aflibercept, 1 mg | 8 | 20 | 650 | $1,010 | $1.3M |
Showing 1–10 of 1033
Other providers in the same ZIP code as Rector & Visitors Of The University Of Virginia, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Brent Portz | VA | Internal Medicine Physician | $658.7K | $0 |
| Timothy Bender | VA | Diagnostic Radiology Physician | $329.1K | $0 |
| Leslie Olsakovsky | VA | Ophthalmology Physician | $299.6K | $0 |
| Krista Isaac | VA | Hematology & Oncology Physician | $288.1K | $0 |
| Corina Rusu | VA | Dermatology Physician | $279.9K | $0 |
| Bruce Urban | VA | Diagnostic Radiology Physician | $260.2K | $13.4K |
| Jean-martin Gingras | VA | Diagnostic Radiology Physician | $269.7K | $0 |
| Diana Pham | VA | Physical Medicine & Rehabilitation Physician | $269.2K | $0 |
| Christopher Mudge | VA | Diagnostic Radiology Physician | $201K | $59.1K |
| Smitha Kuppalli | VA | Dermatology Physician | $258.8K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.